The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10241 malaria professionals are enjoying the free benefits of MalariaWorld today

anti-malarials

Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine-tolerance molecular markers following 18 years of artemisinin-based combination therapy use in Mpumalanga Province, South Africa (2001–2018)

August 27, 2019 - 21:47 -- Open Access
Author(s): 
Jaishree Raman, Frank M. Kagoro, Aaron Mabuza, Gillian Malatje, Anthony Reid, John Frean and Karen I. Barnes
Reference: 
Malaria Journal 2019 18:280, 22 August 2019

The ability of Plasmodium falciparum parasites to develop resistance to widely used anti-malarials threatens malaria control and elimination efforts. Regular drug efficacy monitoring is essential for ensuring effective treatment policies. In low transmission settings where therapeutic efficacy studies are often not feasible, routine surveillance for molecular markers associated with anti-malarial resistance provides an alternative for the early detection of emerging resistance. Such a longitudinal survey of changes in the prevalence of selected molecular markers of resistance was conducted in the malaria-endemic regions of Mpumalanga Province, South Africa, where malaria elimination at a district-level is being pursued.

Medical Treatment: 

In vitro anti-malarial interaction and gametocytocidal activity of cryptolepine

December 28, 2017 - 16:56 -- Open Access
Tags: 
Author(s): 
Arnold Donkor Forkuo, Charles Ansah, Kwesi Boadu Mensah, Kofi Annan, Ben Gyan, Anjo Theron, Dalu Mancama and Colin W. Wright
Reference: 
Malaria Journal 2017 16:496, 28 December 2017

The findings of this study shed light on the high gametocytocidal properties of C. sanguinolenta and cryptolepine attributing their potent anti-malarial activity mainly to their effect on both the sexual and asexual stages of the parasite.

Region: 
Medical Treatment: 

The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg)

May 25, 2017 - 08:11 -- Open Access
Author(s): 
Geoffrey Dow and Bryan Smith
Reference: 
Malaria Journal 2017 16:209, 19 May 2017

Tafenoquine (TQ) is an 8-aminoquinoline anti-malarial being developed for malaria prophylaxis.

Medical Treatment: 

Immunity as a predictor of anti-malarial treatment failure: a systematic review

April 26, 2017 - 15:31 -- Open Access
Tags: 
Author(s): 
Katherine O’Flaherty, Julia Maguire, Julie A. Simpson and Freya J. I. Fowkes
Reference: 
Malaria Journal 2017 16:158, 20 April 2017

Naturally acquired malarial immunity is associated with reduced anti-malarial treatment failure in malaria endemic populations.

Medical Treatment: 

The malaria testing and treatment market in Kinshasa, Democratic Republic of the Congo, 2013

March 2, 2017 - 15:35 -- Open Access
Author(s): 
Godéfroid Mpanya, Antoinette Tshefu and Joris Losimba Likwela
Reference: 
Malaria Journal 2017 16:94, 28 February 2017

While the vast majority of anti-malarial medicines distributed to patients in Kinshasa province are sold within the private sector, availability of malaria testing and appropriate treatment for malaria is alarmingly low.

Medical Treatment: 

Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review

November 8, 2016 - 17:07 -- Open Access
Tags: 
Author(s): 
Bipin Adhikari, Nicola James, Phaik Yeong Cheah, et al.
Reference: 
Malaria Journal 2016 15:523, 2 November 2016

The mean population coverage was over 80% but incomplete reporting of calculation methods limits conclusions and comparisons between studies.

Medical Treatment: 

Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres

March 18, 2015 - 16:32 -- Open Access
Tags: 
Author(s): 
Benjamin Mordmüller, Christian Supan, Peter G Kremsner, et al.
Reference: 
Malaria Journal 2015, 14:117 (18 March 2015)

IV inoculation of PfSPZ is safe, well tolerated and highly reproducible. It shall further accelerate development of anti-malarial interventions through standardization and facilitation of CHMI.

Medical Treatment: 

In vitro and in vivo anti-malarial activity of limonoids isolated from the residual seed biomass from Carapa guianensis (andiroba) oil production

August 20, 2014 - 06:53 -- Open Access
Tags: 
Author(s): 
Pereira TB, Rocha e Silva LF, Amorim RC, Melo MR, Zacardi de Souza RC, Eberlin MN, Lima ES, Vasconcellos MC, Pohlit AM
Reference: 
Malaria Journal 2014, 13 :317 (13 August 2014)

6α-acetoxygedunin is an abundant natural product present in C. guianensis residual seed materials that exhibits significant in vivo anti-malarial properties.

Medical Treatment: 

Malaria case management in Papua New Guinea following the introduction of a revised treatment protocol

December 3, 2013 - 10:48 -- Open Access
Tags: 
Author(s): 
Pulford J, Kurumop SF, Ura Y, Siba PM, Mueller I, Hetzel MW
Reference: 
Malaria Journal 2013, 12 :433 (27 November 2013)
MalariaWorld

PNG has achieved high coverage of malaria RDTs and AL at the health centre level, but these resources have yet to reach the majority of aid-posts.

Medical Treatment: 

Detecting Foci of Malaria Transmission with School Surveys: A Pilot Study in the Gambia

July 10, 2013 - 08:45 -- Open Access
Tags: 
Author(s): 
Ebako N. Takem, Muna Affara, Umberto D'Alessandro, et al.
Reference: 
PLoS ONE 8(6): e67108
MalariaWorld

This survey shows that malaria prevalence and seroprevalence before the transmission season were highly heterogeneous.

Country: 
Medical Treatment: 

Pages

Subscribe to RSS - anti-malarials